How This CEO Consumerized Cancer Diagnostics Into A $13B Enterprise
A decade ago, Exact Sciences launched Cologuard, impacting the fight against colorectal cancer. Its growth of 7000% is in part…
56,070€
4,39%
Echtzeit-Aktienkurs Exact Sciences Corp.
Bid:
Ask:
Nachrichten zur Exact Sciences Corp. Aktie
Exact Sciences EVP sells $140k in company stock By Investing.com
Exact Sciences EVP sells $140k in company stock…
Citi sees Exact Sciences shares climbing after rivals data disappoints By Investing.com
Citi sees Exact Sciences shares climbing after rivals data disappoints…
Exact Sciences (EXAS) Oncoguard Esophagus Test Looks Promising
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.…
Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau
…
Exact Sciences (EXAS) BLUE-C Study Results Published in NEJM
Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.…
Cathie Wood Darling Could Pop On Its Next-Gen Colon Cancer Test
Exact Sciences is hoping to launch an next-generation version of Cologuard in 2025.…
5 Small Biotech ETFs to Watch (Updated 2024)
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…